Halozyme Therapeutics, Inc. Share Price
NASDAQ: HALOHealthcare
Live Halozyme Therapeutics, Inc. Share Price Chart
O H L
Halozyme Therapeutics, Inc. Performance Overview
Days Range
▼
$109.67Low
$111.70High
Markets Today
| Previous Close | $109.68 |
|---|---|
| Open | $109.81 |
| Volume | 888,952 |
| Day's Range | $109.67 - $111.70 |
| 52W Range | $61.23 - $111.15 |
| Market Cap | $12.31 B |
Historical Performance
| 1M Returns | +4.57 |
|---|---|
| 3M Returns | +60.00 |
| 6M Returns | +72.32 |
| 1Y Returns | +43.04 |
| 5Y Returns | +160.89 |
| 10Y Returns | +807.95 |
Halozyme Therapeutics, Inc. Fundamentals
| Market Cap | $12.31 B |
|---|---|
| Dividend yield | 0.00 |
| PE Ratio | 32.40 |
| PEG Ratio | N/A |
| Revenue | $1.40 B |
| ROE TTM | 1.54 |
| EPS TTM | $3.35 |
| Quarterly Earnings Growth YOY | N/A |
| PB Ratio | 86.15 |
| EBITDA | $890.64 M |
| Profit Margin | 22.69 |
| Market Cap | $12.31 B |
|---|---|
| Dividend yield | 0.00 |
| PE Ratio | 32.40 |
| PEG Ratio | N/A |
| Revenue | $1.40 B |
| ROE TTM | 1.54 |
| EPS TTM | $3.35 |
|---|---|
| Quarterly Earnings Growth YOY | N/A |
| PB Ratio | 86.15 |
| EBITDA | $890.64 M |
| Profit Margin | 22.69 |
Halozyme Therapeutics, Inc. Profit & Loss
Quarterly
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Total Revenue + | $264.86 M | $325.72 M | $354.26 M | $451.77 M | $376.71 M | $481.00 M |
| Gross Profit + | $216.46 M | $279.36 M | $299.02 M | $373.00 M | $297.47 M | $401.83 M |
| Operating Income | $141.53 M | $202.44 M | $217.92 M | -$44.19 M | $184.52 M | $287.65 M |
| EBITDA | $161.98 M | $222.94 M | $238.34 M | $267.38 M | $218.25 M | $321.62 M |
| Interest Expense | -$4.53 M | -$4.39 M | -$4.30 M | -$4.91 M | -$5.51 M | -$5.59 M |
| Depreciation | $20.45 M | $20.50 M | $20.42 M | $311.57 M | $33.73 M | $33.97 M |
| Income Before Tax | $143.83 M | $204.94 M | $218.96 M | -$100.85 M | $180.33 M | $284.90 M |
| Income Tax Expense | $25.73 M | $39.78 M | $43.73 M | $40.74 M | $30.28 M | $54.99 M |
| Net Income + | $118.09 M | $165.16 M | $175.22 M | -$141.59 M | $150.05 M | $229.91 M |
| Net Profit Margin | 44.59% | 50.71% | 49.46% | -31.34% | 39.83% | 47.8% |
Halozyme Therapeutics, Inc. Financials Balance Sheet In USD
Quarterly
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Share Capital | $123.00 K | $118.00 K | $118.00 K | $118.00 K | $118.00 K | $114.00 K |
| Reserve & Surplus | $474.55 M | $332.63 M | $479.89 M | $36.69 M | $192.13 M | $143.43 M |
| Non-Current Liabilities | $1.56 B | $1.59 B | $880.09 M | $2.30 B | $2.09 B | $2.09 B |
| Current Liabilities | $150.38 M | $134.28 M | $837.23 M | $177.09 M | $363.21 M | $344.44 M |
| Total Liabilities | $1.71 B | $1.72 B | $1.72 B | $2.48 B | $2.45 B | $2.43 B |
| Fixed Assets | $456.88 M | $437.83 M | $419.96 M | $1.06 B | $1.03 B | $1.01 B |
| Current Assets | $1.26 B | $1.12 B | $1.33 B | $825.21 M | $1.00 B | $933.02 M |
| Total Assets | $2.20 B | $2.05 B | $2.22 B | $2.53 B | $2.67 B | $2.58 B |
Halozyme Therapeutics, Inc. Cash Flow
Quarterly
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Net Income | $118.09 M | $165.16 M | $175.22 M | -$141.59 M | $150.05 M | $229.91 M |
| Operating Cash Flow | $154.22 M | $99.71 M | $178.60 M | $219.03 M | $180.08 M | $240.89 M |
| Investing Cash Flow | -$90.42 M | $84.79 M | $201.61 M | -$741.79 M | -$2.88 M | -$62.66 M |
| Financing Cash Flow | -$3.32 M | -$298.97 M | -$22.40 M | $239.51 M | -$1.61 M | -$326.25 M |
| Change in Cash | $60.48 M | -$114.47 M | $357.80 M | -$283.24 M | $175.59 M | -$148.02 M |
Halozyme Therapeutics, Inc. Return Calculator
The Halozyme Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Returns Estimator
Based on past performance of this fund
ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$26,235
Invested Amount$10,000
Est. Returns$16,235
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Popular Stocks
FAQs
What is the share price of Halozyme Therapeutics, Inc. today?
Halozyme Therapeutics, Inc. (HALO) share price as of September 18, 2026 is $110.29. If you are investing from India, you can always check the valuation in the INR before investing.
Can Indian Investors purchase shares of Halozyme Therapeutics, Inc.?
Yes, Indian Investors can invest in the Halozyme Therapeutics, Inc. (HALO) Share by opening an international trading account with Angel One.
How can I purchase Halozyme Therapeutics, Inc. shares in India?
Purchasing Halozyme Therapeutics, Inc. (HALO) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Halozyme Therapeutics, Inc. (HALO) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Can I buy Fractional shares of Halozyme Therapeutics, Inc.?
Yes, you can purchase fractional shares of Halozyme Therapeutics, Inc. (HALO) or any other US company shares in Angel One for any dollar amount.
What is the market capitalization value of Halozyme Therapeutics, Inc.?
The market capitalization of Halozyme Therapeutics, Inc. on September 18, 2026, is $12.31 B.
In which sector Halozyme Therapeutics, Inc. belongs?
Halozyme Therapeutics, Inc. operates in the Healthcare sector, specifically in the Healthcare industry.
What documents are required to invest in Halozyme Therapeutics, Inc. stocks?
In order to invest in Halozyme Therapeutics, Inc. (HALO) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.
Diversify Your Portfolio with US Stocks
Invest in Wall Street Giants from India
